Sesen Bio, Inc.

NasdaqCM:SESN 株式レポート

時価総額：US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio マネジメント

マネジメント 基準チェック /34

主要情報

Thomas Cannell

最高経営責任者

US$4.9m

報酬総額

CEO給与比率11.34%
CEO在任期間4.6yrs
CEOの所有権0.05%
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間3.1yrs

経営陣の近況

Recent updates

Seeking Alpha • Sep 21

Sesen Bio and Carisma Therapeutics announce merger agreement

Sesen Bio (NASDAQ:SESN) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. The combined company expected to have ~$180M of cash, equivalents and marketable securities at close, including $30M from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Also, the cash runway of combined company expected to enable multiple clinical readouts across Carisma programs. The combined company is expected to operate under the name Carisma Therapeutics and trade on Nasdaq under the ticker symbol “CARM”.
Seeking Alpha • Aug 08

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Sesen Bio press release (NASDAQ:SESN): Q2 GAAP EPS of -$0.16 misses by $0.03. Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of June 30, 2022, compared to $151.1 million as of June 30, 2021. Shares -1.82% PM.
Seeking Alpha • Jul 27

Sesen Bio granted additional time period for regaining compliance

Nasdaq Listing Qualifications department notified Sesen Bio (NASDAQ:SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its non-compliance letter and was granted time until July 25, 2022, to regain compliance with the minimum bid price requirement. The stock will be transferred to the Nasdaq Capital Market effective July 28, 2022 and will continue to trade under the current symbol. Shares trading 2% down premarket
Seeking Alpha • Jul 18

Sesen Bio slips after decision to pause U.S. studies for lead asset

The shares of cancer-focused biotech Sesen Bio (NASDAQ:SESN) traded lower in the pre-market Monday after the company announced its decision to pause further development of its lead asset Vicineum in the U.S. Sesen (SESN) noted that after discussions with the FDA, the company reassessed the development path for Vicineum, including a Phase 3 trial for the treatment in non-muscle invasive bladder cancer (NMIBC). The decision to pause further studies allows the company to save cash as it explores potential strategic alternatives to maximize shareholder value, according to the management. Additionally, Sesen (SESN) expects to form a partnership for the further development of Vicineum. However, the company’s Chief Executive, Dr. Thomas Cannell, noted that the current commercial environment of NMIBC also led to its decision. “We have also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage,” he said. In Aug. 2021, the FDA declined to approve Vicineum for the treatment of BCG-unresponsive NMIBC.
Seeking Alpha • Jun 02

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company's flagship drug Vicineum. Subsequently, management has started a strategic review. SESN trades at $0.58/share vs $0.75/share of net cash.
分析記事 • Apr 17

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Dec 05

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Nov 24

Sesen Bio: Interesting Price Drop After CRL

Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Seeking Alpha • Nov 17

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
Seeking Alpha • Aug 23

Sesen Bio: The Road Ahead

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the path ahead.
分析記事 • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...
分析記事 • Feb 18

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Today is shaping up negative for Sesen Bio, Inc. ( NASDAQ:SESN ) shareholders, with the analysts delivering a...
分析記事 • Jan 26

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sesen Bio...
分析記事 • Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Sesen Bio, Inc.'s...

CEO報酬分析

Sesen Bio の収益と比較して、Thomas Cannell の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2022n/an/a

-US$20m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

US$48m

Mar 31 2022n/an/a

US$54m

Dec 31 2021US$5mUS$558k

-US$336k

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$118m

Mar 31 2021n/an/a

-US$119m

Dec 31 2020US$2mUS$533k

-US$23m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$60m

Dec 31 2019US$1mUS$520k

-US$107m

Sep 30 2019n/an/a

-US$81m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$198k

-US$34m

報酬と市場: Thomasの 総報酬 ($USD 4.92M ) は、 US市場 ($USD 7.00M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Thomasの報酬は増加しましたが、会社は利益を上げていません。

CEO

Thomas Cannell (60 yo)

4.6yrs
在職期間
US$4,921,698
報酬

Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Monica Forbes
CFO & Treasurer3.6yrsUS$1.87m0.036%
$ 926.9k
Glen MacDonald
Chief Technology Officer6.1yrsUS$1.27m0.025%
$ 645.2k
Gregory L. Verdine
Co-Founderno dataデータなしデータなし
Elly Ryu
Corporate Controller & Principal Accounting Officer1.9yrsデータなし0.050%
$ 1.3m
Erin Clark
Vice President of Corporate Strategy & Investor Relationsno dataデータなしデータなし
Mark Sullivan
General Counsel3.6yrsUS$1.15m0.022%
$ 566.6k
Steve Barbera
Vice President of Market Access1.8yrsデータなしデータなし
David Brooks
Senior Vice President of Clinical Development5.8yrsデータなしデータなし
Dennis Kim
Chief Medical Officer4.3yrsUS$709.28kデータなし
Kirstin Anderson
Senior Director of Finance1.9yrsデータなしデータなし
Minori Rosales
Chief Development Officer1.2yrsデータなしデータなし
3.6yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: SESNの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Thomas Cannell
President4.6yrsUS$4.92m0.048%
$ 1.2m
Neal Shore
Member of Medical Advisory Boardno dataデータなしデータなし
Jay Duker
Independent Chairman of the Board8.2yrsUS$251.28k0%
$ 0
Michael Jewett
Independent Director1.7yrsUS$469.77k0%
$ 0
Carrie Bourdow
Independent Director3.1yrsUS$215.91k0%
$ 0
Jason Keyes
Independent Director3.1yrsUS$219.01k0%
$ 0
Wassim Kassouf
Member of Medical Advisory Boardno dataデータなしデータなし
Rian Dickstein
Member of Medical Advisory Boardno dataデータなしデータなし
Thomas Keane
Member of Medical Advisory Boardno dataデータなしデータなし
Donald Lamm
Member of Medical Advisory Boardno dataデータなしデータなし
Alon Weizer
Member of Medical Advisory Boardno dataデータなしデータなし
Michael O'Donnell
Member of Medical Advisory Boardno dataデータなしデータなし
3.1yrs
平均在職期間
59.5yo
平均年齢

経験豊富なボード: SESNの 取締役会 は 経験豊富 であると考えられます ( 3.1年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/03/08 21:18
終値2023/03/07 00:00
収益2022/12/31
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Sesen Bio, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC